Q&A
Exclusive interviews with industry leaders
-
Former U.S. patent head on why federal march-in rights for drugs would be a ‘devastating’ mistake
A Biden administration proposal to seize patents for drugs deemed too pricey would have a ripple effect that cuts into the heart of innovation, says former U.S. PTO head Andrei Iancu.
Michael Gibney • March 14, 2024 -
Into the unknown: Tarsus’ CEO on its launch strategies in a new disease category
The company scored a first-in-class nod for its eye med last year, which treats a common but frequently undiagnosed condition.
Meagan Parrish • March 8, 2024 -
Biogen partner NeuroSense seeks a role in the ALS revolution
Results from a mid-stage study for a new ALS drug have been strong, and NeuroSense is looking to join a small but sturdy wave of companies bringing new treatments to market.
Michael Gibney • Feb. 29, 2024 -
For Moderna, COVID vaccines were a ‘proof of concept’ — now comes the big test
Following Moderna’s COVID-19 vaccine success, therapeutics head Dr. Kyle Holen discusses scaling mRNA development to bring candidates to the finish line in oncology and more.
Amy Baxter • Feb. 23, 2024 -
Why a former BMS exec calls her new CEO role ‘unfinished business’ in cancer care
With a focus on her “three pillars” of being a CEO, Caroline Loew explains how she’s building a new company culture at an Alkermes spinoff — and a pipeline that offers a next-gen approach to oncology.
Alexandra Pecci • Feb. 6, 2024 -
‘1 plus 1 equals 3’ — the co-CEO model in pharma
Amylyx Pharmaceuticals’ co-founders and co-CEOs Josh Cohen and Justin Klee explain their approach to dual leadership and why it can be a good fit in life sciences.
Meagan Parrish • Jan. 26, 2024 -
One biotech’s 3 gene therapy hurdles: delivery, delivery and delivery
4DMT’s David Kirn is looking to the future of gene therapy with delivery methods that change the paradigm.
Michael Gibney • Jan. 10, 2024 -
This biotech aims to expand the CRISPR toolkit for more disease targets in the liver and brain
Arbor Biotechnologies is looking past CRISPR’s recent regulatory wins and into the next stage of gene editing.
Michael Gibney • Dec. 19, 2023 -
The many ‘myths’ of clinical trial diversity, and Genentech’s fight to disrupt them
Genentech’s chief diversity officer Quita Highsmith is on a crusade to prove that much of what the industry believes about clinical trial diversity is wrong.
Michael Gibney • Dec. 14, 2023 -
A former CDC head on key R&D areas, public trust and if we learned anything from COVID-19
Dr. Julie Gerberding, now president and CEO of the Foundation for the National Institutes of Health, shares lessons learned from a long career in academic, public health and industry.
Meagan Parrish • Dec. 13, 2023 -
Bristol Myers’ commercial chief on the industry’s ‘seismic’ changes over 27 years and what’s coming next
Adam Lenkowsky’s unique vantage point on the major transformations shaping BMS and the industry as a whole.
Michael Gibney • Dec. 12, 2023 -
Patients who hide pills and advocacy offices that could get ‘raided’ — a Gilead leader on navigating global HIV
Gilead Sciences’ SVP of global patient solutions discusses how she’s managing some of the world’s most complicated health issues and what’s next in HIV innovation.
Alexandra Pecci • Dec. 11, 2023 -
The head of AstraZeneca’s new digital health business on how the pharma is leveraging tech
Cristina Durán, formerly AstraZeneca’s chief digital officer of R&D and now head of digital health business Evinova, believes data will help pharma screen and treat patients earlier in their disease.
Michael Gibney • Nov. 28, 2023 -
Organon’s chief medical officer wants to change how the world sees women’s health
Dr. Juan Camilo Arjona Ferreira joined Organon in September and says the company is “like a lighthouse in women’s health” in its visibility and focus.
Michael Gibney • Nov. 22, 2023 -
AstraZeneca showed the pandemic isn’t over for immunocompromised patients. What’s next?
Dr. Paul Moss, a hematology expert in the U.K., conducted a study with AstraZeneca showing the alarming extent to which immunocompromised patients are burdened with COVID-19.
Michael Gibney • Nov. 16, 2023 -
23andMe CEO Anne Wojcicki’s vision for changing healthcare as a ‘full-fledged biotech’
23andMe always had bigger aims than at-home genetics testing. In this in-depth interview, the company’s founder explains its foray into pharma, drug R&D, solving cold cases and more.
Alexandra Pecci • Nov. 7, 2023 -
Wisp’s ‘bold and unapologetic approach’ to women’s sexual and reproductive health
In the role of interim CEO of Wisp, Monica Cepak aims to break down barriers and expand access via telehealth.
Alexandra Pecci • Oct. 31, 2023 -
Red Jacket: Dr. Mark Goldberg, a clinical innovator
Dr. Mark Goldberg has continually been at the cutting edge of technologies and ideas, including now as chairman and CEO of Allucent.
Alexandra Pecci • Oct. 27, 2023 -
Red Jacket: Dr. Jeremy Levin, a transformational leader
A consummate life sciences executive who has led with boldness and devotion, Dr. Jeremy Levin considers himself a participant as well as a leader.
Michael Gibney • Oct. 27, 2023 -
Red Jacket: Helen Sabzevari, an immunotherapy pioneer
Precigen’s CEO is pushing for her next therapeutic breakthrough with innovative cell and gene therapy platforms.
Meagan Parrish • Oct. 27, 2023 -
Red Jacket: Ken Getz, a champion of clinical trials
Ken Getz has spent his career improving clinical research for the benefit of patients, the life sciences industry and other R&D stakeholders.
Alexandra Pecci • Oct. 27, 2023 -
Red Jacket: Adele Gulfo, a commercialization guru
With a knack for melding science and patient-focused marketing techniques, the CEO of the biopharma commercial unit at Sumitomo Pharma America has notched blockbuster successes throughout her career.
Karissa Waddick • Oct. 27, 2023 -
Actor and epilepsy advocate Greg Grunberg wants the world to ‘talk about it’
The actor of “Heroes” and “Star Wars: The Force Awakens” fame is starring in another role as a patient advocate for people with epilepsy.
Michael Gibney • Oct. 19, 2023 -
To close the pediatric innovation gap, this biotech has to think differently
Day One Biopharmaceuticals is bucking the cancer drug development trend by working with children and adults simultaneously.
Alexandra Pecci • Oct. 11, 2023 -
5 minutes with — IDEA Pharma’s Mike Rea
The CEO on the secrets of innovative pharma companies, his record collection and what he’d always rather be doing.
Meagan Parrish • Oct. 11, 2023